Organoid Prediction of Treatment Response in Multi-Drug Resistant Lung Cancer Patients 公告 2024-12-17 17:16:41 Written By Kym Kilbourne Title: Organoid Prediction of Treatment Response in Multi-Drug Resistant Lung Cancer Patients ClinicalTrials.gov ID: NCT05669586 Sponsor: Affiliated Hospital of Jiangnan University Provider of Information: Affiliated Hospital of Jiangnan University (Responsible Party) Last Update Posted: 2024-03-19 Study Overview Brief Summary This is a single-center, single-arm, open-label exploratory clinical study. The purpose of this study is to evaluate the consistency and accuracy of patient-derived organoid (PDO) models in predicting the clinical efficacy of anticancer drugs and to infer and select personalized treatment plans for multi-drug resistant lung cancer patients. The study involves multiple lines of standard therapy. Detailed Description The challenge of multi-drug resistance following multiple lines of treatment for lung cancer lacks a standard consensus in clinical diagnosis and treatment, with related treatment plans still being explored and their efficacy unknown. Patient-derived organoid cells (PDOs) have become a reliable tumor model for in vitro drug testing. PDOs are personalized tumor models that share similar characteristics with the original tumor. This model can maintain the molecular and cellular composition of the primary tumor, reflect the heterogeneity of the primary tumor, achieve high-throughput rapid screening of drug sensitivity in vitro, accurately predict the patient's drug response, and thus provide rapid drug feedback for clinical use. In recent years, lung cancer organoids have been rapidly established, capable of reproducing the tissue structure of primary pulmonary tumors, screening the sensitivity of treatment drugs, formulating lung cancer treatment plans, and achieving personalized lung cancer therapy. There is a high match between patients and their PDO responses, with an accuracy of 84.43%, sensitivity of 78.01%, and specificity of 91.97%. Official Title A Single-Arm, Single-Center Clinical Trial of Patient-Derived Lung Cancer Organoids for Predicting Treatment Responses in Patients with Multi-Drug Resistant Lung Cancer Condition Lung Cancer Organoids Intervention/Treatment Drug: Anticancer treatment guided by organoid drug sensitivity testing Other Study ID Numbers 136286 Contact and Location Information Study Contact Name: Dr. Liu Quan Phone: 15995299079 Email: quanliu@jiangnan.edu.cn; quanliu.lq@outlook.com Study Link: https://clinicaltrials.gov/study/NCT05669586?term=organoid%20Guided&aggFilters=status:rec&rank=5 Kym Kilbourne
Organoid Prediction of Treatment Response in Multi-Drug Resistant Lung Cancer Patients 公告 2024-12-17 17:16:41 Written By Kym Kilbourne Title: Organoid Prediction of Treatment Response in Multi-Drug Resistant Lung Cancer Patients ClinicalTrials.gov ID: NCT05669586 Sponsor: Affiliated Hospital of Jiangnan University Provider of Information: Affiliated Hospital of Jiangnan University (Responsible Party) Last Update Posted: 2024-03-19 Study Overview Brief Summary This is a single-center, single-arm, open-label exploratory clinical study. The purpose of this study is to evaluate the consistency and accuracy of patient-derived organoid (PDO) models in predicting the clinical efficacy of anticancer drugs and to infer and select personalized treatment plans for multi-drug resistant lung cancer patients. The study involves multiple lines of standard therapy. Detailed Description The challenge of multi-drug resistance following multiple lines of treatment for lung cancer lacks a standard consensus in clinical diagnosis and treatment, with related treatment plans still being explored and their efficacy unknown. Patient-derived organoid cells (PDOs) have become a reliable tumor model for in vitro drug testing. PDOs are personalized tumor models that share similar characteristics with the original tumor. This model can maintain the molecular and cellular composition of the primary tumor, reflect the heterogeneity of the primary tumor, achieve high-throughput rapid screening of drug sensitivity in vitro, accurately predict the patient's drug response, and thus provide rapid drug feedback for clinical use. In recent years, lung cancer organoids have been rapidly established, capable of reproducing the tissue structure of primary pulmonary tumors, screening the sensitivity of treatment drugs, formulating lung cancer treatment plans, and achieving personalized lung cancer therapy. There is a high match between patients and their PDO responses, with an accuracy of 84.43%, sensitivity of 78.01%, and specificity of 91.97%. Official Title A Single-Arm, Single-Center Clinical Trial of Patient-Derived Lung Cancer Organoids for Predicting Treatment Responses in Patients with Multi-Drug Resistant Lung Cancer Condition Lung Cancer Organoids Intervention/Treatment Drug: Anticancer treatment guided by organoid drug sensitivity testing Other Study ID Numbers 136286 Contact and Location Information Study Contact Name: Dr. Liu Quan Phone: 15995299079 Email: quanliu@jiangnan.edu.cn; quanliu.lq@outlook.com Study Link: https://clinicaltrials.gov/study/NCT05669586?term=organoid%20Guided&aggFilters=status:rec&rank=5 Kym Kilbourne
